Android Apple

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

By Yahoo! Finance   |   3 weeks ago
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

MariTide showed up to 20% average weight loss at one year without a plateau, disappointing Wall Street expectations. The study indicated further weight loss potential beyond 52 weeks, with improvements in cardiometabolic parameters and no impact on bone density.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.